BACKGROUND: Hepatitis A is a major health risk for many human immunodeficiency virus (HIV)-infected individuals. Vaccination is a potentially attractive measure to reduce the incidence of hepatitis A among this population, but data on its safety and immunogenicity are incomplete. METHODS:Ninety HIV-uninfected adults received an inactivated hepatitis A vaccine (VAQTA; Merck), and 90 HIV-infected subjects were randomized, in double-blind fashion, to receive either the vaccine or placebo. The HIV-infected subjects were stratified by CD4 cell count, with 45 subjects having CD4 cell counts of > or =300 cells/mm3 and 45 subjects having CD4 cell counts of <300 cells/mm3. Vaccine was given at weeks 0 and 24 of the study.Results. Seroconversion rates at week 28 of the study were 94% among the HIV-infected subjects and 100% among the HIV-uninfected control subjects. HIV-infected subjects with CD4 cell counts of <300 cells/mm3 had a seroconversion rate of 87%, and HIV-infected subjects with CD4 cell counts of > or =300 cells/mm3 had a seroconversion rate of 100%. The vaccine was generally well tolerated, and no adverse effect on either HIV load or CD4 cell count was found. CONCLUSION: Hepatitis A vaccine was both immunogenic and safe among HIV-infected subjects.
RCT Entities:
BACKGROUND:Hepatitis A is a major health risk for many human immunodeficiency virus (HIV)-infected individuals. Vaccination is a potentially attractive measure to reduce the incidence of hepatitis A among this population, but data on its safety and immunogenicity are incomplete. METHODS: Ninety HIV-uninfected adults received an inactivated hepatitis A vaccine (VAQTA; Merck), and 90 HIV-infected subjects were randomized, in double-blind fashion, to receive either the vaccine or placebo. The HIV-infected subjects were stratified by CD4 cell count, with 45 subjects having CD4 cell counts of > or =300 cells/mm3 and 45 subjects having CD4 cell counts of <300 cells/mm3. Vaccine was given at weeks 0 and 24 of the study.Results. Seroconversion rates at week 28 of the study were 94% among the HIV-infected subjects and 100% among the HIV-uninfected control subjects. HIV-infected subjects with CD4 cell counts of <300 cells/mm3 had a seroconversion rate of 87%, and HIV-infected subjects with CD4 cell counts of > or =300 cells/mm3 had a seroconversion rate of 100%. The vaccine was generally well tolerated, and no adverse effect on either HIV load or CD4 cell count was found. CONCLUSION:Hepatitis A vaccine was both immunogenic and safe among HIV-infected subjects.
Authors: Nancy F Crum-Cianflone; Kenneth Wilkins; Andrew W Lee; Anthony Grosso; Michael L Landrum; Amy Weintrob; Anuradha Ganesan; Jason Maguire; Stephanie Klopfer; Carolyn Brandt; William P Bradley; Mark R Wallace; Brian K Agan Journal: J Infect Dis Date: 2011-06-15 Impact factor: 5.226
Authors: Pierre Alex Crisinel; Klara Maria Posfay-Barbe; Christoph Aebi; Jean-Jacques Cheseaux; Christian Kahlert; Christoph Rudin; David Nadal; Claire-Anne Siegrist Journal: Clin Vaccine Immunol Date: 2012-08-29
Authors: Robert J Yetman; Julie S Shepard; Anton Duke; Jon E Stek; Maria Petrecz; Stephanie O Klopfer; Barbara J Kuter; Florian P Schödel; Andrew W Lee Journal: Hum Vaccin Immunother Date: 2013-06-06 Impact factor: 3.452
Authors: Jessica A Kahn; Jiahong Xu; Bill G Kapogiannis; Bret Rudy; René Gonin; Nancy Liu; Craig M Wilson; Carol Worrell; Kathleen E Squires Journal: Clin Infect Dis Date: 2013-05-10 Impact factor: 9.079
Authors: Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris Journal: MMWR Recomm Rep Date: 2020-07-03